Abstract
Tacrolimus (FK506) is a widely used and clinically important immunosuppressant drug that can be produced by fermentation of Streptomyces tsukubaensis. The industrial strains are typically obtained through multiple rounds of mutagenesis and screening, a labor-intensive process. We have established an efficient yeast cell based screening method for the evolutionary process of high-FK506-yielding strain. The S. tsukubaensis strains of different FK506 yields were tested for zone of growth inhibition of the wild type and calcineurin mutant (cnb1∆) yeast strains. We found that different FK506 yields correspond well to altered yeast growth inhibitions. Based on the combinational inhibition effects of FK506 with different antifungals that have been frequently reported, we also tested the zone of inhibition by addition of fluconazole, amphotericin B and caspofungin to the medium. In the end, for the best screening performance, we systemically evaluated the strategy when different yeast strains and different antifungals were used according to the clarity, size, and divergence of the inhibition circles. Using different yeast strains and antifungals, we successfully broadened the screening spectrum. An efficient high-FK506-yield S. tsukubaensis screening method has been established and optimized.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The authors confirm that the data supporting the findings of this study are available within the article.
References
Barreiro C, Martinez-Castro M (2014) Trends in the biosynthesis and production of the immunosuppressant tacrolimus (FK506). Appl Microbiol Biotechnol 98:497–507
Barreiro C, Prieto C, Sola-Landa A, Solera E, Martinez-Castro M, Perez-Redondo R, Garcia-Estrada C, Aparicio JF, Fernandez-Martinez LT, Santos-Aberturas J, Salehi-Najafabadi Z, Rodriguez-Garcia A, Tauch A, Martin JF (2012) Draft genome of Streptomyces tsukubaensis NRRL 18488, the producer of the clinically important immunosuppressant tacrolimus (FK506). J Bacteriol 194:3756–3757
Borba-Santos LP, Reis de Sa LF, Ramos JA, Rodrigues AM, de Camargo ZP, Rozental S, Ferreira-Pereira A (2017) Tacrolimus increases the effectiveness of itraconazole and fluconazole against Sporothrix spp. Front Microbiol 8:1759
Cen Y-K, Li M-H, Wang Q, Zhang J-M, Yuan J-C, Wang Y-S, Liu Z-Q, Zheng Y (2023) Evolutionary engineering of Fusarium fujikuroi for enhanced production of gibberellic acid. Process Biochem 125:7–14
Chen YL, Lehman VN, Averette AF, Perfect JR, Heitman J (2013) Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. PLoS One 8:e57672
Chen YL, Yu SJ, Huang HY, Chang YL, Lehman VN, Silao FG, Bigol UG, Bungay AA, Averette A, Heitman J (2014) Calcineurin controls hyphal growth, virulence, and drug tolerance of Candida tropicalis. Eukaryot Cell 13:844–854
Connolly S, Quasi-Woode D, Waldron L, Eberly C, Waters K, Muller EM, Kingsbury TJ (2018) Calcineurin regulatory subunit calcium-binding domains differentially contribute to calcineurin signaling in Saccharomyces cerevisiae. Genetics 209:801–813
De Cesare GB, Hafez A, Stead D, Llorens C, Munro CA (2022) Biomarkers of caspofungin resistance in Candida albicans isolates: A proteomic approach. Virulence 13:1005–1018
Espinel-Ingroff A, Cantón E, Pemán J (2012) Antifungal susceptibility testing of filamentous fungi. Curr. Fungal Infect. Rep. 6:41–50
Ferraboschi P, Colombo D, DeMieri M, Grisenti M (2012) Evaluation, synthesis and characterization of tacrolimus impurities. J Antibiot 65(7):349–354
Fu LF, Tao Y, Jin MY, Jiang H (2016) Improvement of FK506 production by synthetic biology approaches. Biotechnol. Lett. 38:2015–2021
Garg V, Jain GK, Nirmal J, Kohli K (2013) Topical tacrolimus nanoemulsion, a promising therapeutic approach for uveitis. Med Hypotheses 81:901–904
Gurudevan S, Francis AP, Jayakrishnan A (2018) Amphotericin B-albumin conjugates: Synthesis, toxicity and anti-fungal activity. Eur J Pharm Sci 115:167–174
Hannah J, Casian A, D’Cruz D (2016) Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. Autoimmun. Rev. 15:93–101
Karababa M, Valentino E, Pardini G, Coste AT, Bille J, Sanglard D (2006) CRZ1, a target of the calcineurin pathway in Candida albicans. Mol Microbiol. 59:1429–1451
Kubica TF, Denardi LB, Azevedo MI, Oliveira V, Severo LC, Santurio JM, Alves SH (2016) Antifungal activities of tacrolimus in combination with antifungal agents against fluconazole-susceptible and fluconazole-resistant Trichosporon asahii isolates. Braz J Infect Dis 20:539–545
Lee Y, Lee KT, Lee SJ, Beom JY, Hwangbo A, Jung JA, Song MC, Yoo YJ, Kang SH, Averette AF, Heitman J, Yoon YJ, Cheong E, Bahn YS (2018) In vitro and in vivo assessment of FK506 analogs as novel antifungal drug candidates. Antimicrob Agents Chemother 62:10–1128
Li W, Shrivastava M, Lu H, Jiang Y (2021) Calcium-calcineurin signaling pathway in Candida albicans: a potential drug target. Microbiol Res 249:126786
Lu H, Shrivastava M, Whiteway M, Jiang Y (2021) Candida albicans targets that potentially synergize with fluconazole. Crit Rev Microbiol 47:323–337
Monaghan P, Leneghan DB, Shaw W, Bell A (2017) The antimalarial action of FK506 and rapamycin: evidence for a direct effect on FK506-binding protein PfFKBP35. Parasitology 144:869–876
Nambu M, Covel JA, Kapoor M, Li X, Moloney MK, Numa MM, Soltow QA, Trzoss M, Webb P, Webb RR 2nd, Mutz M (2017) A calcineurin antifungal strategy with analogs of FK506. Bioorg Med Chem Lett 27:2465–2471
Nishimoto M, Koh H, Tokuwame A, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Koh S, Yoshimura T, Nanno S, Nakamae M, Hirose A, Nakashima Y, Nakane T, Hino M, Nakamae H (2017) Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation. Br J Clin Pharmacol 83:2000–2007
Onyewu C, Blankenship JR, Del Poeta M, Heitman J (2003) Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother 47:956–964
Papon N, Goldman GH (2021) Unraveling caspofungin resistance in Cryptococcus neoformans. Mbio 12:10–1128
Park HS, Chow EW, Fu C, Soderblom EJ, Moseley MA, Heitman J, Cardenas ME (2016) Calcineurin Targets involved in stress survival and fungal virulence. PLoS Pathog 12:e1005873
Sen Kaya S, Kiraz N, Baris A, Turan D, Oz Y, Dag I, Aygun G (2021) Effects of calcineurin inhibitors, cyclosporine A and tacrolimus (FK506), on the activity of antifungal drugs against Candida spp. J Med Microbiol. https://doi.org/10.1099/jmm.0.001354
Shirazi F, Kontoyiannis DP (2013) The calcineurin pathway inhibitor tacrolimus enhances the in vitro activity of azoles against Mucorales via apoptosis. Eukaryot Cell 12:1225–1234
Thewes S (2014) Calcineurin-Crz1 signaling in lower eukaryotes. Eukaryot Cell 13:694–705
Thompson GR, Soriano A, Skoutelis A, Vazquez JA, Honore PM, Horcajada JP, Spapen H, Bassetti M, Ostrosky-Zeichner L, Das AF, Viani RM, Sandison T, Pappas PG (2021) Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE Trial. Clin Infect Dis 73:e3647–e3655
Wu QB, Zhang XY, Chen XA, Li YQ (2021) Improvement of FK506 production via metabolic engineering-guided combinational strategies in Streptomyces tsukubaensis. Microb Cell Fact 20:166
Ye L, Ye R, Hu F, Wang G (2021) Combination of atmospheric and room temperature plasma (ARTP) mutagenesis, genome shuffling and dimethyl sulfoxide (DMSO) feeding to improve FK506 production in Streptomyces tsukubaensis. Biotechnol Lett 43:1809–1820
Funding
This work was supported by the National Natural Science Foundation of China (No. 32070123 and No. 32100079).
Author information
Authors and Affiliations
Contributions
Y-KC created the idea and wrote the draft. N-YH and W-YZ implemented the laboratory work. Z-QL and Y-GZ provided financial support and finalized the draft.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests and the manuscript has been approved by all authors for publication.
Ethical statements
This article does not contain any studies with human participants or animals performed by any of the authors.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cen, YK., He, NY., Zhou, WY. et al. Development of a yeast cell based method for efficient screening of high yield tacrolimus production strain. 3 Biotech 14, 26 (2024). https://doi.org/10.1007/s13205-023-03870-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13205-023-03870-y